298 related articles for article (PubMed ID: 31589023)
21. In vivo biodistribution of prion- and GM1-targeted polymersomes following intravenous administration in mice.
Stojanov K; Georgieva JV; Brinkhuis RP; van Hest JC; Rutjes FP; Dierckx RA; de Vries EF; Zuhorn IS
Mol Pharm; 2012 Jun; 9(6):1620-7. PubMed ID: 22536790
[TBL] [Abstract][Full Text] [Related]
22. Application of the Phage Display Technology for the Development of Peptide- mediated Drug Delivery Systems through the Blood-Brain Barrier.
Suárez VM; Vispo NS; Ramos OS
Curr Pharm Biotechnol; 2021; 22(11):1394-1403. PubMed ID: 33397231
[TBL] [Abstract][Full Text] [Related]
23. Peptide drug delivery into the central nervous system.
Prokai L
Prog Drug Res; 1998; 51():95-131. PubMed ID: 9949860
[TBL] [Abstract][Full Text] [Related]
24. Ligand-cascading nano-delivery devices to enable multiscale targeting of anti-neurodegenerative therapeutics.
Mullis AS; Schlichtmann BW; Narasimhan B; Cademartiri R; Mallapragada SK
Biomed Mater; 2018 Feb; 13(3):034102. PubMed ID: 29332842
[TBL] [Abstract][Full Text] [Related]
25. In vivo phage display identifies novel peptides for cardiac targeting.
Ivanova A; Kohl F; González-King Garibotti H; Chalupska R; Cvjetkovic A; Firth M; Jennbacken K; Martinsson S; Silva AM; Viken I; Wang QD; Wiseman J; Dekker N
Sci Rep; 2024 May; 14(1):12177. PubMed ID: 38806609
[TBL] [Abstract][Full Text] [Related]
26. Advances in Targeted Drug Delivery Approaches for the Central Nervous System Tumors: The Inspiration of Nanobiotechnology.
Meng J; Agrahari V; Youm I
J Neuroimmune Pharmacol; 2017 Mar; 12(1):84-98. PubMed ID: 27449494
[TBL] [Abstract][Full Text] [Related]
27. The Role of Natural Compounds and their Nanocarriers in the Treatment of CNS Inflammation.
Khadka B; Lee JY; Park DH; Kim KT; Bae JS
Biomolecules; 2020 Oct; 10(10):. PubMed ID: 33019651
[TBL] [Abstract][Full Text] [Related]
28. A critical evaluation of drug delivery from ligand modified nanoparticles: Confounding small molecule distribution and efficacy in the central nervous system.
Cook RL; Householder KT; Chung EP; Prakapenka AV; DiPerna DM; Sirianni RW
J Control Release; 2015 Dec; 220(Pt A):89-97. PubMed ID: 26471392
[TBL] [Abstract][Full Text] [Related]
29. Effects of snake venom polypeptides on central nervous system.
Osipov A; Utkin Y
Cent Nerv Syst Agents Med Chem; 2012 Dec; 12(4):315-28. PubMed ID: 23270323
[TBL] [Abstract][Full Text] [Related]
30. Crossing the blood-brain-barrier with nanoligand drug carriers self-assembled from a phage display peptide.
Wu LP; Ahmadvand D; Su J; Hall A; Tan X; Farhangrazi ZS; Moghimi SM
Nat Commun; 2019 Oct; 10(1):4635. PubMed ID: 31604928
[TBL] [Abstract][Full Text] [Related]
31. Nanodelivery systems for overcoming limited transportation of therapeutic molecules through the blood-brain barrier.
Kim KT; Lee HS; Lee JJ; Park EK; Lee BS; Lee JY; Bae JS
Future Med Chem; 2018 Nov; 10(22):2659-2674. PubMed ID: 30499740
[TBL] [Abstract][Full Text] [Related]
32. Pharmaceutical Targeting of the Brain.
Krizbai IA; Nyúl-Tóth Á; Bauer HC; Farkas AE; Traweger A; Haskó J; Bauer H; Wilhelm I
Curr Pharm Des; 2016; 22(35):5442-5462. PubMed ID: 27464716
[TBL] [Abstract][Full Text] [Related]
33. Applications of nanotechnology in drug delivery to the central nervous system.
Saeedi M; Eslamifar M; Khezri K; Dizaj SM
Biomed Pharmacother; 2019 Mar; 111():666-675. PubMed ID: 30611991
[TBL] [Abstract][Full Text] [Related]
34. Interactions of IGF-1 with the blood-brain barrier in vivo and in situ.
Pan W; Kastin AJ
Neuroendocrinology; 2000 Sep; 72(3):171-8. PubMed ID: 11025411
[TBL] [Abstract][Full Text] [Related]
35. Targeting specific cells in the brain with nanomedicines for CNS therapies.
Zhang F; Lin YA; Kannan S; Kannan RM
J Control Release; 2016 Oct; 240():212-226. PubMed ID: 26686078
[TBL] [Abstract][Full Text] [Related]
36. A Peptide Targeting Inflammatory CNS Lesions in the EAE Rat Model of Multiple Sclerosis.
Boiziau C; Nikolski M; Mordelet E; Aussudre J; Vargas-Sanchez K; Petry KG
Inflammation; 2018 Jun; 41(3):932-947. PubMed ID: 29516383
[TBL] [Abstract][Full Text] [Related]
37. Liposome-based glioma targeted drug delivery enabled by stable peptide ligands.
Wei X; Gao J; Zhan C; Xie C; Chai Z; Ran D; Ying M; Zheng P; Lu W
J Control Release; 2015 Nov; 218():13-21. PubMed ID: 26428462
[TBL] [Abstract][Full Text] [Related]
38. From naturally-occurring neurotoxic agents to CNS shuttles for drug delivery.
Soddu E; Rassu G; Giunchedi P; Sarmento B; Gavini E
Eur J Pharm Sci; 2015 Jul; 74():63-76. PubMed ID: 25892455
[TBL] [Abstract][Full Text] [Related]
39. Intranasal delivery of biologics to the central nervous system.
Lochhead JJ; Thorne RG
Adv Drug Deliv Rev; 2012 May; 64(7):614-28. PubMed ID: 22119441
[TBL] [Abstract][Full Text] [Related]
40. Upconversion Nanoparticle-Based Strategy for Crossing the Blood-Brain Barrier to Treat the Central Nervous System Disease.
Fu L; Chung R; Shi B
Methods Mol Biol; 2019; 2054():263-282. PubMed ID: 31482461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
